Larimar Therapeutics Inc [NASDAQ: LRMR] surged by $0.66 during the normal trading session on Wednesday and reaching a high of $5.21 during the day while it closed the day at $5.1.
Larimar Therapeutics Inc stock has also gained 25.00% of its value over the past 7 days. However, LRMR stock has inclined by 56.92% in the 3 months of the year. Over the past six months meanwhile, it has gained 120.78% and lost -27.86% year-on date.
The market cap for LRMR stock reached $436.51 million, with 64.03 million shares outstanding and 48.59 million shares in the current float. Compared to the average trading volume of 1.42M shares, LRMR reached a trading volume of 7798203 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Larimar Therapeutics Inc [LRMR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LRMR shares is $19.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LRMR stock is a recommendation set at 1.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Larimar Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2025. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on October 16, 2024, representing the official price target for Larimar Therapeutics Inc stock. Previously, the target price had yet another raise to $22, while Wedbush analysts kept a Outperform rating on LRMR stock.
The Price to Book ratio for the last quarter was 2.72, with the Price to Cash per share for the same quarter was set at 1.62.
LRMR stock trade performance evaluation
Larimar Therapeutics Inc [LRMR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.00. With this latest performance, LRMR shares gained by 37.10% in over the last four-week period, additionally plugging by 120.78% over the last 6 months – not to mention a rise of 31.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LRMR stock in for the last two-week period is set at 74.14, with the RSI for the last a single of trading hit 0.36, and the three-weeks RSI is set at 0.33 for Larimar Therapeutics Inc [LRMR]. The present Moving Average for the last 50 days of trading for this stock 3.82, while it was recorded at 4.50 for the last single week of trading, and 3.23 for the last 200 days.
Larimar Therapeutics Inc (LRMR) Capital Structure & Debt Analysis
According to recent financial data for Larimar Therapeutics Inc. ( LRMR), the Return on Equity (ROE) stands at -60.25%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -51.55%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Larimar Therapeutics Inc’s Return on Invested Capital (ROIC) is -80.90%, showcasing its effectiveness in deploying capital for earnings.
Larimar Therapeutics Inc (LRMR) Efficiency & Liquidity Metrics
Based on Larimar Therapeutics Inc’s (LRMR) latest financial statements, the Debt-to-Equity Ratio is 0.04%, indicating its reliance on debt financing relative to shareholder equity.
Larimar Therapeutics Inc (LRMR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Larimar Therapeutics Inc. (LRMR) effectively leverages its workforce, generating an average of -$1535230.77 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.46% and a Quick Ratio of 5.46%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Larimar Therapeutics Inc [LRMR] stock
With the latest financial reports released by the company, Larimar Therapeutics Inc posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.13. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LRMR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Larimar Therapeutics Inc go to -1.38%.
Larimar Therapeutics Inc [LRMR]: Institutional Ownership
There are presently around $83.80%, or 84.71%% of LRMR stock, in the hands of institutional investors. The top three institutional holders of LRMR stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 21.23 million shares, which is approximately 33.278%. RA CAPITAL MANAGEMENT, L.P., holding 6.05 million shares of the stock with an approximate value of $$43.83 million in LRMR stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $$31.63 million in LRMR stock with ownership which is approximately 6.8609%.
